| 1.98 -0.03 (-1.49%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.43 | 1-year : | 2.62 |
| Resists | First : | 2.08 | Second : | 2.25 |
| Pivot price | 2.05  |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.01 |
MA(20) : | 2.09 |
| MA(100) : | 1.93  |
MA(250) : | 1.95 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 10 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 2.41 | Low : | 1.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SEER ] has closed above bottom band by 14.0%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.02 - 2.03 | 2.03 - 2.04 |
| Low: | 1.94 - 1.96 | 1.96 - 1.98 |
| Close: | 1.95 - 1.98 | 1.98 - 2 |
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Fri, 28 Aug 2026
Seer president & CFO David Horn sells $14,809 of stock - Investing.com
Tue, 11 Aug 2026
Seer, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SEER) 2026-08-11 - Seeking Alpha
Mon, 03 Aug 2026
Seer to Report Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
Thu, 30 Jul 2026
Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares - Stock Titan
Thu, 30 Jul 2026
Seer Confirms Receipt of Further Revised Unsolicited - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 181 (K) |
| Shares Short P.Month | 130 (K) |
| EPS | -1.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | 0 % |
| Operating Margin | -543 % |
| Return on Assets (ttm) | -15.3 % |
| Return on Equity (ttm) | -26.5 % |
| Qtrly Rev. Growth | -23.4 % |
| Gross Profit (p.s.) | 0.12 |
| Sales Per Share | 0.25 |
| EBITDA (p.s.) | -1.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -1.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 7.7 |
| Price to Cash Flow | -2.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|